- Home
- INMB vs IVVD Comparison
INMB vs IVVD Comparison
Compare INMB & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- IVVD
- Stock Information
- Founded
- INMB 2015
- IVVD 2020
- Country
- INMB United States
- IVVD United States
- Employees
- INMB N/A
- IVVD N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- IVVD Health Care
- Exchange
- INMB Nasdaq
- IVVD Nasdaq
- Market Cap
- INMB 112.0M
- IVVD 116.8M
- IPO Year
- INMB 2019
- IVVD 2021
- Fundamental
- Price
- INMB $4.40
- IVVD $0.44
- Analyst Decision
- INMB Strong Buy
- IVVD Strong Buy
- Analyst Count
- INMB 2
- IVVD 4
- Target Price
- INMB $21.00
- IVVD $7.89
- AVG Volume (30 Days)
- INMB 215.6K
- IVVD 981.7K
- Earning Date
- INMB 10-31-2024
- IVVD 11-14-2024
- Dividend Yield
- INMB N/A
- IVVD N/A
- EPS Growth
- INMB N/A
- IVVD N/A
- EPS
- INMB N/A
- IVVD N/A
- Revenue
- INMB $42,000.00
- IVVD $11,564,000.00
- Revenue This Year
- INMB N/A
- IVVD N/A
- Revenue Next Year
- INMB N/A
- IVVD $486.65
- P/E Ratio
- INMB N/A
- IVVD N/A
- Revenue Growth
- INMB N/A
- IVVD N/A
- 52 Week Low
- INMB $4.32
- IVVD $0.40
- 52 Week High
- INMB $14.74
- IVVD $5.20
- Technical
- Relative Strength Index (RSI)
- INMB 37.57
- IVVD 29.58
- Support Level
- INMB $4.74
- IVVD $0.57
- Resistance Level
- INMB $5.16
- IVVD $0.51
- Average True Range (ATR)
- INMB 0.38
- IVVD 0.06
- MACD
- INMB -0.05
- IVVD -0.01
- Stochastic Oscillator
- INMB 5.56
- IVVD 13.30
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.